Skip to content
The Policy VaultThe Policy Vault

Tafinlar (dabrafenib) — Cigna

Non-Small Cell Lung Cancer

Initial criteria

  • Patient has recurrent, advanced, or metastatic disease
  • Patient has BRAF V600 mutation-positive disease

Approval duration

1 year